These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 21679968)
1. Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone. Wichniak A; Skowerska A; Chojnacka-Wójtowicz J; Tafliński T; Wierzbicka A; Jernajczyk W; Jarema M J Psychiatr Res; 2011 Oct; 45(10):1381-6. PubMed ID: 21679968 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design. Canive JM; Miller GA; Irwin JG; Moses SN; Thoma RJ; Edgar JC; Sherwood A; Torres F; Lanoue M; Lewis S; Hanlon FM; Weisend MP; Mead V; Tuason VB Psychopharmacol Bull; 2006; 39(1):105-16. PubMed ID: 17065975 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371 [TBL] [Abstract][Full Text] [Related]
4. Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone. Konarzewska B; Waszkiewicz N; Galińska B; Szulc A Neuro Endocrinol Lett; 2013; 34(4):322-8. PubMed ID: 23803867 [TBL] [Abstract][Full Text] [Related]
5. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. Dossenbach MR; Kratky P; Schneidman M; Grundy SL; Metcalfe S; Tollefson GD; Belmaker RH J Clin Psychiatry; 2001; 62 Suppl 2():28-34. PubMed ID: 11232749 [TBL] [Abstract][Full Text] [Related]
6. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. Mozes T; Ebert T; Michal SE; Spivak B; Weizman A J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):393-403. PubMed ID: 16958565 [TBL] [Abstract][Full Text] [Related]
7. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642 [TBL] [Abstract][Full Text] [Related]
8. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial. Sacchetti E; Valsecchi P; Parrinello G; Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497 [TBL] [Abstract][Full Text] [Related]
9. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Casey DE; Daniel DG; Wassef AA; Tracy KA; Wozniak P; Sommerville KW Neuropsychopharmacology; 2003 Jan; 28(1):182-92. PubMed ID: 12496955 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. Zalsman G; Carmon E; Martin A; Bensason D; Weizman A; Tyano S J Child Adolesc Psychopharmacol; 2003; 13(3):319-27. PubMed ID: 14642020 [TBL] [Abstract][Full Text] [Related]
11. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial. Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255 [TBL] [Abstract][Full Text] [Related]
12. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Conley RR; Mahmoud R Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400 [TBL] [Abstract][Full Text] [Related]
13. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935 [TBL] [Abstract][Full Text] [Related]
14. Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. van Bruggen J; Tijssen J; Dingemans P; Gersons B; Linszen D Int Clin Psychopharmacol; 2003 Nov; 18(6):341-6. PubMed ID: 14571154 [TBL] [Abstract][Full Text] [Related]
15. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan. Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T Psychiatry Clin Neurosci; 2012 Jun; 66(4):313-21. PubMed ID: 22624736 [TBL] [Abstract][Full Text] [Related]
16. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials. Ardizzone I; Nardecchia F; Marconi A; Carratelli TI; Ferrara M Psychopharmacol Bull; 2010; 43(2):45-66. PubMed ID: 21052042 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959 [TBL] [Abstract][Full Text] [Related]
18. [Sleep quality and daytime sleepiness in schizophrenia spectrum disorders during antipsychotic treatment]. Wichniak A; Waliniowska E; Wierzbicka A; Czasak K; Musińska I; Szatkowska E; Jernajczyk W; Jarema M Psychiatr Pol; 2009; 43(2):193-202. PubMed ID: 19697789 [TBL] [Abstract][Full Text] [Related]
19. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820 [TBL] [Abstract][Full Text] [Related]
20. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R; J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]